Rafa Laboratories

Prescription and Over-the-Counter Medicines

Health Tech & Life Sciences
Acquired by FIMI Opportunity Funds on Oct 2020

Company Overview

Snapshot

Founded in January 1937, Rafa Laboratories operates with 51–200 employees. The company has raised a total of $200 million across one public funding round. In October 2020, Rafa Laboratories was acquired by FIMI Opportunity Funds.

Business overview

Rafa Laboratories is a pharmaceutical company specializing in the marketing, manufacturing, and distribution of consumer health products, prescription, and over-the-counter medicines. The company develops proprietary and generic formulations, and also markets drugs produced by international corporations such as Dr. Falk Pharma and Boehringer Ingelheim. Rafa Laboratories operates within the Health Tech & Life Sciences sector, focusing on pharmaceuticals and drug discovery and development.

Strategic signal

In July 2026, Rafa Laboratories completed an offer for sale that netted FIMI NIS 500 million. This event signals a significant financial return for its controlling investor, FIMI Opportunity Funds, and indicates a strategic move to potentially re-evaluate the company's market position or ownership structure following its prior acquisition.

Company Intelligence Q&A

What was a significant recent development for Rafa Laboratories?
In July 2026, Rafa Laboratories completed an offer for sale that generated NIS 500 million for FIMI Opportunity Funds.
When did Rafa Laboratories receive FDA approval for its midazolam autoinjector?
Rafa Laboratories received FDA approval for its 10 mg midazolam autoinjector in August 2022, designed to treat seizures caused by nerve agent exposure.
What was the valuation when FIMI Opportunity Funds acquired Rafa Laboratories?
FIMI Opportunity Funds acquired Rafa Laboratories in October 2020 at a valuation of NIS 700 million.
Did Rafa Laboratories announce plans for an IPO?
In May 2026, Rafa Laboratories announced plans for an IPO with a target valuation of NIS 2.2 billion.
What strategic partnership did Rafa Laboratories form in May 2019?
In May 2019, Rafa Laboratories and Panaxia signed a collaboration agreement with PlantEXT to research and manufacture medical cannabis suppositories for inflammatory bowel disease.

External links